Abstract:Natural killer (NK) cell-based immunotherapy represents a promising strategy to overcome the bottlenecks of cancer treatment. However, the therapeutic efficacy is greatly limited by downregulation of recognition ligands on the tumor cell surface, and the immunosuppressive effects can be thwarted by the tumor microenvironment such as secretion of transforming growth factor-beta (TGF-β), which could stunt the NK cell-mediated immune response. To overcome these limitations, herein we developed a nanoemulsion system (SSB NMs) to co-deliver TGF-β inhibitor and selenocysteine (SeC) to achieve amplified anticancer efficacy. SSB NMs significantly enhanced the lytic potency of NK92 cells by 2.1-fold. Moreover, a subtoxic dose of SSB NMs effectively sensitized MDA-MB-231 triple-negative breast cancer (TNBC) cells to NK cells derived from seven clinical patients, resulting in an up to 13.8-fold increase in cancer lysis. Mechanistic studies reveal that the sensitizing effects relied on natural killer group 2, member D (NKG2D)/NKG2D ligands (NKG2DLs) signaling with the involvement of DNA damage response. SSB NMs also effectively restrained TGF-β/TGF-β RI/Smad2/3 signaling, which thus enhanced NKG2DL expression on tumor cells and stimulated NKG2D surface expression on NK92 cells, ultimately contributing to the enhanced immune response. Furthermore, SSB NMs sustained release of SeC and TGF-β inhibitor and synergized with NK92 cells to induce significant anticancer effects <i>in vivo</i>. Together, this study not only demonstrates a simple strategy for the design of a nanoemulsion to co-deliver synergistic drugs but also sheds light on the application and action mechanisms in NK cell adaptive therapy against breast cancer, especially TNBCs.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acsnano.9b10103?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acsnano.9b10103</a>.Figures of the immunosensitizing effects of NK92 cells induced by SSB NMs against MDA-MB-231 cancer cells; cytolytic activities of NK92 cells after preincubated with SeC against cancer cells; SSB NMs augment the cytolytic activities of NK92 cells on HCC1937 and MDA-MB-468 cells; SSB NMs augment the cytolytic activities of NK92 cells by determining LDH release; characterization of NK cells from patients; cellular uptake and intracellular localization of Cou6-labeled and SSB NMs in MDA-MB-231 cells; expression of DR4/5, TRAIL, and FasL; comet assay and immunocytochemistry detecting DNA damage; cell cycle analysis by flow cytometry; antimigration effects of SeC and SSB NMs; tumor images and tumor inhibition ratio; hematological analysis; H&E-stained images of major organs; H&E-stained images and clinical chemistry evaluation in orthotopic tumor model (<a class="ext-link" href="/doi/suppl/10.1021/acsnano.9b10103/suppl_file/nn9b10103_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.

RETRACTED: Seleno-cyclodextrin Sensitises Human Breast Cancer Cells to TRAIL-induced Apoptosis Through DR5 Induction and NF-κB Suppression.

2-Tellurium-bridged Β-Cyclodextrin, a Thioredoxin Reductase Inhibitor, Sensitizes Human Breast Cancer Cells to TRAIL-induced Apoptosis Through DR5 Induction and NF-κB Suppression.

Novel Insights into the Synergistic Interaction of a Thioredoxin Reductase Inhibitor and TRAIL: the Activation of the ASK1-ERK-Sp1 Pathway

[Synergistic Effects and Mechanisms of Combined Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand and Chemotherapeutic Drugs or Radiotherapy in Killing Laryngeal Squamous Carcinoma Cells in Vitro].

Regulation of Ca2+ Signaling for Drug-Resistant Breast Cancer Therapy with Mesoporous Silica Nanocapsule Encapsulated Doxorubicin/siRNA Cocktail

Tunicamycin enhances human colon cancer cells to TRAIL-induced apoptosis by JNK-CHOP-mediated DR5 upregulation and the inhibition of the EGFR pathway

Synergism Between Thioredoxin Reductase Inhibitor Ethaselen and Sodium Selenite in Inhibiting Proliferation and Inducing Death of Human Non-Small Cell Lung Cancer Cells.

Reversal of the Apoptotic Resistance of Non-Small-Cell Lung Carcinoma Towards TRAIL by Natural Product Toosendanin

N-Acetyl-Glucosamine Sensitizes Non-Small Cell Lung Cancer Cells to TRAIL-Induced Apoptosis by Activating Death Receptor 5

Enhanced extrinsic apoptosis of therapy-induced senescent cancer cells using a death receptor 5 (DR5) selective agonist

Extracellular Vesicle Delivery of TRAIL Eradicates Resistant Tumor Growth in Combination with CDK Inhibition by Dinaciclib.

Boosting Natural Killer Cell-Based Cancer Immunotherapy with Selenocystine/Transforming Growth Factor-Beta Inhibitor-Encapsulated Nanoemulsion

Selenium promotes immunogenic radiotherapy against cervical cancer metastasis through evoking P53 activation

Anti-recurrence/metastasis and chemosensitization therapy with thioredoxin reductase-interfering drug delivery system

Radiotherapy Sensitization by Tumor-Specific TRAIL Gene Targeting Improves Survival of Mice Bearing Human Non–Small Cell Lung Cancer

Combination Of Trail And Actinomycin D Liposomes Enhances Antitumor Effect In Non-Small Cell Lung Cancer

Combination of TRAIL gene therapy and chemotherapy enhances antitumor and antimetastasis effects in chemosensitive and chemoresistant breast cancers

Trail-Armed Er Nanosomes Induce Drastically Enhanced Apoptosis In Resistant Tumor In Combination With The Antagonist Of Iaps (Azd5582)

Selenium-containing Thioredoxin Reductase Inhibitor Ethaselen Sensitizes Non-Small Cell Lung Cancer to Radiotherapy

Selenium-driven enhancement of synergistic cancer chemo-/radiotherapy by targeting nanotherapeutics